Market capitalization | GBP61.31b |
Enterprise Value | GBP74.38b |
PER (TTM) P/E ratio | 13.61 |
EV/FCF (TTM) EV/FCF | 12.69 |
EV/Sales (TTM) EV/Sales | 2.42 |
P/S ratio (TTM) P/S ratio | 1.99 |
P/B ratio (TTM) P/B ratio | 4.43 |
Dividend yield | 3.71% |
Last dividend (FY23) | GBP0.56 |
As a Free StocksGuide user, you can view scores for all 6,952 stocks worldwide.
23 Analysts have issued a GlaxoSmithKline forecast:
23 Analysts have issued a GlaxoSmithKline forecast:
Mar '24 |
+/-
%
|
||
Turnover | 30,740 30,740 |
6%
6%
|
|
Gross income | 21,769 21,769 |
7%
7%
|
|
EBITDA | 9,973 9,973 |
16%
16%
|
EBIT (operating result) EBIT | 7,215 7,215 |
14%
14%
|
Net profit | 4,484 4,484 |
68%
68%
|
Figures in millions GBP.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Head office | United Kingdom |
CEO | Emma Walmsley |
Employees | 70,212 |
Founded | 1999 |
Website | www.gsk.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.